TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Evaluation of Treatment of Amblyopia in 7 To <18 Year Olds
Brief Summary: The goals of this study are:

* To determine the response rate of treatment of amblyopia in 7 to \<18 year olds.
* To determine the frequency of recurrence of amblyopia in 7 to \<18 year olds after discontinuation of amblyopia treatment.


Options:
A: Arm Label: I-BiTTM game; Type: EXPERIMENTAL; Interventions: Device: I-BiTTM game | Arm Label: Non-I-BiTTM game; Type: ACTIVE_COMPARATOR; Interventions: Device: Non-I-BiTTM game | Arm Label: I-BiTTM DVD; Type: EXPERIMENTAL; Interventions: Device: I-BiTTM DVD | Intervention Type: DEVICE; Name: I-BiTTM game; Assigned to Arm(s): I-BiTTM game | Intervention Type: DEVICE; Name: Non-I-BiTTM game; Assigned to Arm(s): Non-I-BiTTM game | Intervention Type: DEVICE; Name: I-BiTTM DVD; Assigned to Arm(s): I-BiTTM DVD
B: Intervention Type: DEVICE; Name: Eye patch; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: spectacles; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atropine; Assigned to Arm(s): N/A
C: Arm Label: Binocular Computer Game Treatment; Type: EXPERIMENTAL; Interventions: Other: iPad® | Arm Label: Continued Spectacle Correction; Type: ACTIVE_COMPARATOR; Interventions: Other: Spectacle correction | Intervention Type: OTHER; Name: iPad®; Assigned to Arm(s): Binocular Computer Game Treatment | Intervention Type: OTHER; Name: Spectacle correction; Assigned to Arm(s): Continued Spectacle Correction
D: Arm Label: Recommendation of Patching; Type: ACTIVE_COMPARATOR; Interventions: Other: Patching Therapy | Arm Label: Recommendation of Patching and interactive binocular treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Patching Therapy, Device: Interactive Binocular Treatment System | Intervention Type: OTHER; Name: Patching Therapy; Assigned to Arm(s): Recommendation of Patching, Recommendation of Patching and interactive binocular treatment | Intervention Type: DEVICE; Name: Interactive Binocular Treatment System; Assigned to Arm(s): Recommendation of Patching and interactive binocular treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Evaluation of Treatment of Amblyopia in 7 To <18 Year Olds
Brief Summary: The goals of this study are:

* To determine the response rate of treatment of amblyopia in 7 to \<18 year olds.
* To determine the frequency of recurrence of amblyopia in 7 to \<18 year olds after discontinuation of amblyopia treatment.


Options:
A: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Procedure: Near activities | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine, Procedure: Near activities | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Patching | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Atropine, Patching
B: Intervention Type: DEVICE; Name: Eye patch; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Spectacles; Assigned to Arm(s): N/A
C: Intervention Type: DEVICE; Name: Eye patch; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: spectacles; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atropine; Assigned to Arm(s): N/A
D: Intervention Type: DEVICE; Name: 6 hours occlusion by patching; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 12 hours occlusion by patching; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Evaluation of Treatment of Amblyopia in 7 To <18 Year Olds
Brief Summary: The goals of this study are:

* To determine the response rate of treatment of amblyopia in 7 to \<18 year olds.
* To determine the frequency of recurrence of amblyopia in 7 to \<18 year olds after discontinuation of amblyopia treatment.


Options:
A: Arm Label: Intensive; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Drug: Atropine | Arm Label: Weaning; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Drug: Atropine | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Intensive | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Intensive | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Weaning | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Weaning
B: Intervention Type: DEVICE; Name: Eye patch; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: spectacles; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atropine; Assigned to Arm(s): N/A
C: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Patching
D: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Procedure: Near activities | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine, Procedure: Near activities | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Patching | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Atropine, Patching

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Evaluation of Treatment of Amblyopia in 7 To <18 Year Olds
Brief Summary: The goals of this study are:

* To determine the response rate of treatment of amblyopia in 7 to \<18 year olds.
* To determine the frequency of recurrence of amblyopia in 7 to \<18 year olds after discontinuation of amblyopia treatment.


Options:
A: Intervention Type: DEVICE; Name: Eye patch; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Spectacles; Assigned to Arm(s): N/A
B: Arm Label: I-BiT Plus; Type: EXPERIMENTAL; Interventions: Device: I-Bit plus | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: I-Bit plus; Assigned to Arm(s): I-BiT Plus
C: Intervention Type: DEVICE; Name: Eye patch; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: spectacles; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atropine; Assigned to Arm(s): N/A
D: Arm Label: Near activities; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch, Procedure: Near activities | Arm Label: Distance activities; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch, Procedure: Distance activities | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Distance activities, Near activities | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Near activities | Intervention Type: PROCEDURE; Name: Distance activities; Assigned to Arm(s): Distance activities

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Everyday Memory in At-Risk Elderly
Brief Summary: The purpose of this study is to determine whether classes on memory training will help older adults to improve or maintain their daily activities.


Options:
A: Arm Label: Telerehabilitation group; Type: EXPERIMENTAL; Interventions: Behavioral: Telerehabilitation group | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telerehabilitation group; Assigned to Arm(s): Telerehabilitation group
B: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Acupuncture & educ; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Acupuncture and patient education | Arm Label: 2. Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Acupuncture and patient education; Assigned to Arm(s): Acupuncture & educ
D: Intervention Type: PROCEDURE; Name: Memory Training; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy
Brief Summary: The purpose of this trial is to evaluate the efficacy and safety of risperidone versus placebo in subjects with Major Depressive Disorder with sub-optimal response to antidepressant therapy.


Options:
A: Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A
B: Arm Label: Continue sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Arm Label: Augment with mirtazapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline, Drug: Mirtazapine | Arm Label: Switch to mirtazapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirtazapine | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Augment with mirtazapine, Continue sertraline | Intervention Type: DRUG; Name: Mirtazapine; Assigned to Arm(s): Augment with mirtazapine, Switch to mirtazapine
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Antidepressant + placebo | Arm Label: Cariprazine 0.1 - 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Antidepressant + cariprazine (0.1-0.3 mg/day) | Arm Label: Cariprazine 1.0 - 2.0 mg; Type: EXPERIMENTAL; Interventions: Drug: Antidepressant + cariprazine (1-2 mg/d) | Intervention Type: DRUG; Name: Antidepressant + placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Antidepressant + cariprazine (0.1-0.3 mg/day); Assigned to Arm(s): Cariprazine 0.1 - 0.3 mg | Intervention Type: DRUG; Name: Antidepressant + cariprazine (1-2 mg/d); Assigned to Arm(s): Cariprazine 1.0 - 2.0 mg
D: Arm Label: 1: venlafaxine plus aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: venlafaxine XR plus aripiprazole | Arm Label: 2: Placebo Comparator; Type: EXPERIMENTAL; Interventions: Drug: venlafaxine plus placebo | Intervention Type: DRUG; Name: venlafaxine XR plus aripiprazole; Assigned to Arm(s): 1: venlafaxine plus aripiprazole | Intervention Type: DRUG; Name: venlafaxine plus placebo; Assigned to Arm(s): 2: Placebo Comparator

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination With Methotrexate in Controlling Disease Activity in Subjects With Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate
Brief Summary: The purpose of this clinical research study is to learn if Abatacept or Infliximab in combination with Methotrexate demonstrate a greater reduction in disease activity over placebo.


Options:
A: Arm Label: MabThera/Rituxan; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab [MabThera/Rituxan] | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): MabThera/Rituxan | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): MabThera/Rituxan
B: Arm Label: Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Arm Label: Infliximab + MTX (DB); Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab (INF) + MTX, DB | Arm Label: Placebo + MTX (DB); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (PLA) + MTX, DB | Arm Label: Placebo + MTX switched to abatacept + MTX (DB); Type: EXPERIMENTAL; Interventions: Drug: PLA + MTX switched to ABA+ MTX, DB | Arm Label: Abatacept (open-label); Type: EXPERIMENTAL; Interventions: Drug: ABA, open-label (OL) | Intervention Type: DRUG; Name: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB); Assigned to Arm(s): Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]) | Intervention Type: DRUG; Name: Infliximab (INF) + MTX, DB; Assigned to Arm(s): Infliximab + MTX (DB) | Intervention Type: DRUG; Name: Placebo (PLA) + MTX, DB; Assigned to Arm(s): Placebo + MTX (DB) | Intervention Type: DRUG; Name: PLA + MTX switched to ABA+ MTX, DB; Assigned to Arm(s): Placebo + MTX switched to abatacept + MTX (DB) | Intervention Type: DRUG; Name: ABA, open-label (OL); Assigned to Arm(s): Abatacept (open-label)
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate + Methylprednisolone | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate + Infliximab | Intervention Type: DRUG; Name: Infliximab, methylprednisolone, methotrexate; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Methotrexate + Methylprednisolone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Methotrexate + Infliximab; Assigned to Arm(s): C
D: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination With Methotrexate in Controlling Disease Activity in Subjects With Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate
Brief Summary: The purpose of this clinical research study is to learn if Abatacept or Infliximab in combination with Methotrexate demonstrate a greater reduction in disease activity over placebo.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 001
B: Arm Label: CDP870 200mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of CDP870 | Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): CDP870 200mg | Intervention Type: DRUG; Name: Placebo of CDP870; Assigned to Arm(s): Placebo
C: Arm Label: Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Arm Label: Infliximab + MTX (DB); Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab (INF) + MTX, DB | Arm Label: Placebo + MTX (DB); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (PLA) + MTX, DB | Arm Label: Placebo + MTX switched to abatacept + MTX (DB); Type: EXPERIMENTAL; Interventions: Drug: PLA + MTX switched to ABA+ MTX, DB | Arm Label: Abatacept (open-label); Type: EXPERIMENTAL; Interventions: Drug: ABA, open-label (OL) | Intervention Type: DRUG; Name: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB); Assigned to Arm(s): Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]) | Intervention Type: DRUG; Name: Infliximab (INF) + MTX, DB; Assigned to Arm(s): Infliximab + MTX (DB) | Intervention Type: DRUG; Name: Placebo (PLA) + MTX, DB; Assigned to Arm(s): Placebo + MTX (DB) | Intervention Type: DRUG; Name: PLA + MTX switched to ABA+ MTX, DB; Assigned to Arm(s): Placebo + MTX switched to abatacept + MTX (DB) | Intervention Type: DRUG; Name: ABA, open-label (OL); Assigned to Arm(s): Abatacept (open-label)
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: MLTA3698A, Drug: leflunomide, Drug: methotrexate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: adalimumab, Drug: leflunomide, Drug: methotrexate, Drug: placebo | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: leflunomide, Drug: methotrexate, Drug: placebo | Intervention Type: DRUG; Name: MLTA3698A; Assigned to Arm(s): A | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): B | Intervention Type: DRUG; Name: leflunomide; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B, C

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)
Brief Summary: The purpose of this clinical research study is to learn if Irbesartan is superior to placebo in reducing mortality and cardiovascular morbidity in subjects with heart failure with preserved systolic function. The safety of this treatment will also be studied.


Options:
A: Arm Label: BAY94-8862; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Finerenone (BAY94-8862); Assigned to Arm(s): BAY94-8862 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Irbesartan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Irbesartan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: addition of spironolactone; Type: EXPERIMENTAL; Interventions: Drug: spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: spironolactone; Assigned to Arm(s): addition of spironolactone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eplerenone | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Drug: Eplerenone | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind Trial in Ventilated ICU Patients Comparing Treatment With an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status
Brief Summary: Delirium has recently been shown as a predictor of death, increased cost, and longer length of stay in ventilated patients. Sedative and analgesic medications relieve anxiety and pain, but may contribute to patients' transitioning into delirium. It is possible that modifying the paradigm for sedation using novel therapies targeted at different receptors, such as dexmedetomidine targeting alpha2 receptors and sparing the GABA receptors, could provide efficacious sedation yet reduce the development, duration, and severity of acute brain dysfunction (delirium).


Options:
A: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: haloperidol | Intervention Type: DRUG; Name: dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: haloperidol; Assigned to Arm(s): 2
C: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam
D: Arm Label: Early PT OT; Type: EXPERIMENTAL; Interventions: Procedure: early PT OT | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: early PT OT; Assigned to Arm(s): Early PT OT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind Trial in Ventilated ICU Patients Comparing Treatment With an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status
Brief Summary: Delirium has recently been shown as a predictor of death, increased cost, and longer length of stay in ventilated patients. Sedative and analgesic medications relieve anxiety and pain, but may contribute to patients' transitioning into delirium. It is possible that modifying the paradigm for sedation using novel therapies targeted at different receptors, such as dexmedetomidine targeting alpha2 receptors and sparing the GABA receptors, could provide efficacious sedation yet reduce the development, duration, and severity of acute brain dysfunction (delirium).


Options:
A: Intervention Type: PROCEDURE; Name: Sedation management protocol; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Smartcare/PS | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Smartcare/PS; Assigned to Arm(s): 1
C: Arm Label: mechanically ventilated patients; Type: N/A; Interventions: N/A
D: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind Trial in Ventilated ICU Patients Comparing Treatment With an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status
Brief Summary: Delirium has recently been shown as a predictor of death, increased cost, and longer length of stay in ventilated patients. Sedative and analgesic medications relieve anxiety and pain, but may contribute to patients' transitioning into delirium. It is possible that modifying the paradigm for sedation using novel therapies targeted at different receptors, such as dexmedetomidine targeting alpha2 receptors and sparing the GABA receptors, could provide efficacious sedation yet reduce the development, duration, and severity of acute brain dysfunction (delirium).


Options:
A: Arm Label: Ketamine (0.5 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Ketamine (0.5 mg/kg) | Arm Label: Normal saline (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline (placebo) | Arm Label: Ketamine (1 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Ketamine (1 mg/kg) | Intervention Type: DRUG; Name: Ketamine (0.5 mg/kg); Assigned to Arm(s): Ketamine (0.5 mg/kg) | Intervention Type: DRUG; Name: Normal Saline (placebo); Assigned to Arm(s): Normal saline (placebo) | Intervention Type: DRUG; Name: Ketamine (1 mg/kg); Assigned to Arm(s): Ketamine (1 mg/kg)
B: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group
C: Intervention Type: PROCEDURE; Name: Orthogeriatric intervention; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: B